Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Switzerland says U.S. stance on vaccine patent waiver leaves questions

05/06/2021 | 12:53pm EDT

ZURICH, May 6 (Reuters) - The Swiss government said on Thursday a U.S. announcement that it would support waiving intellectual property rights for COVID-19 vaccines was significant but left many questions unanswered.

President Joe Biden on Wednesday threw his support behind waiving intellectual property rights for COVID-19 vaccines and his top trade negotiator, Katherine Tai, backed negotiations at the World Trade Organization.

Switzerland's State Secretariat for Economic Affairs (SECO) said in an emailed statement: "This is an important announcement by the U.S., but many questions remain unanswered about the specific solutions it is considering in this context."

SECO said Switzerland was still convinced that waiving intellectual property rights in the context of the pandemic could not guarantee fair, affordable and rapid access to vaccines, drugs and diagnostic products related to COVID-19.

It said Switzerland would examine the U.S. request and its consequences on the Swiss position, with the United States itself and within the World Trade Organisation.

Swiss company Lonza makes ingredients for Moderna's COVID-19 shot, while Swiss drugmaker Novartis makes COVID-19 vaccines for Germany's CureVac. (Reporting by Silke Koltrowitz; Editing by Andrew Cawthorne and Dan Grebler)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
LONZA GROUP AG 0.73% 665.2 Delayed Quote.16.07%
MODERNA, INC. -2.81% 201.59 Delayed Quote.92.96%
NOVARTIS AG 0.69% 84.89 Delayed Quote.0.77%
ROCHE HOLDING AG 0.70% 346.05 Delayed Quote.11.21%
All news about NOVARTIS AG
06/15NOVARTIS AGá : Gets a Buy rating from Berenberg
MD
06/14NOVARTISá : investigational oral therapy iptacopan (LNP023) shows benefit as mon..
AQ
06/11NOVARTISá : Says Iptacopan Shows Benefits, Safety as Potential Treatment for Blo..
MT
06/11NOVARTIS'á : Iptacopan Shows Positive Results in Rare Blood Disorder Patients
MT
06/11PRESS RELEASEá : Novartis investigational oral -2-
DJ
06/11PRESS RELEASEá : Novartis investigational oral therapy iptacopan (LNP023) shows ..
DJ
06/11Novartis investigational oral therapy iptacopan (LNP023) shows benefit as mon..
DJ
06/11NOVARTIS'á : Entresto Gets Indication For High Blood Pressure Treatment In China
MT
06/10Glencore, Other Swiss Multinationals to Get Government Support Amid G7's New ..
MT
06/09NOVARTISá : Mulls Swiss Plant Closure On Demand Shortage
MT
More news
Financials (USD)
Sales 2021 51 668 M - -
Net income 2021 9 938 M - -
Net Debt 2021 22 978 M - -
P/E ratio 2021 20,9x
Yield 2021 3,49%
Capitalization 211 B 211 B -
EV / Sales 2021 4,52x
EV / Sales 2022 4,23x
Nbr of Employees 110 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 106,54 $
Last Close Price 93,79 $
Spread / Highest target 58,8%
Spread / Average Target 13,6%
Spread / Lowest Target -6,64%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG0.77%210 689
JOHNSON & JOHNSON4.52%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.7.55%221 613
ABBVIE INC.8.10%204 582
ELI LILLY AND COMPANY32.39%203 185